CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Current Assets:
Cash and cash equivalents	$ 180,070	$ 288,266
Accounts receivable, net of allowance of $11,304 in 2025 and $12,585 in 2024	552,378	473,575
Inventories	377,756	381,877
Other current assets	303,623	256,179
Total current assets	1,413,827	1,399,897
Long-Term Assets:
Property and equipment, net	747,380	713,123
Operating lease right-of-use assets	123,228	116,129
Goodwill	414,004	405,100
Intangible assets, net	109,843	111,676
Other long-term assets	542,477	547,518
Total long-term assets	1,936,932	1,893,546
TOTAL ASSETS	3,350,759	3,293,443
Current Liabilities:
Accounts payable	110,408	114,211
Accrued liabilities	530,147	502,119
Credit Facility	398,000	250,000
Current portion of long-term debt	74,995	167,787
Current portion of deferred revenue	35,264	33,799
Total current liabilities	1,148,814	1,067,916
Long-Term Liabilities:
Deferred income tax liabilities	31,865	11,312
Long-term debt, net of current portion	374,842	449,786
Long-term deferred revenue, net of current portion	32,177	26,939
Long-term operating lease liabilities, net of current portion	101,151	97,836
Other long-term liabilities	56,527	44,341
Total long-term liabilities	596,562	630,214
Total liabilities	1,745,376	1,698,130
Commitments and Contingencies (Note 16)
Stockholders’ Equity:
Common stock, $0.10 par value: Authorized: 120,000 shares; Issued: 108,369 shares in 2025 and 107,836 shares in 2024; Outstanding: 79,712 shares in 2025 and 81,604 shares in 2024	10,837	10,784
Additional paid-in capital	1,826,750	1,673,863
Deferred stock units: Outstanding: 59 units in 2025 and 60 units in 2024	6,094	5,885
Retained earnings	6,391,902	5,332,438
Accumulated other comprehensive loss	(68,844)	(93,645)
Treasury stock, at cost: 28,657 shares in 2025 and 26,232 shares in 2024	(6,561,356)	(5,334,012)
Total IDEXX Laboratories, Inc. stockholders’ equity	1,605,383	1,595,313
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 3,350,759	$ 3,293,443